Clinical Trials Logo

C3 Glomerulonephritis clinical trials

View clinical trials related to C3 Glomerulonephritis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04183101 Recruiting - C3 Glomerulopathy Clinical Trials

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

The aim of this cross-over trial is to assess aliskiren, a direct renin inhibitor, as a novel treatment to block complement activation in the kidneys and thereby attenuate renal disease and stabilize or improve kidney function and compare it to the currently used treatment with the angiotensin converting enzyme inhibitor, enalapril, in patients with the complement-mediated renal disease C3 glomerulopathy. Patients will be randomized to one or the other treatment for the first 6 months and then switch to the other treament for the following 2.5 years. Treatment will continue for altogether 3 years for each patient.